NASDAQ:ELVN
Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. reported net income of −$103.7M in fiscal 2025. Free cash flow was −$70.5M, and the diluted share count rose 20.4%.Summary generated from Enliven Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 3, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−27.0%
Debt / equityn/a
Free cash flow−$70.5M
FCF marginn/a
Share count change+20.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −51 | −39 | −84 | −105 | −120 |
| Net income | −51 | −38 | −72 | −89 | −104 |
| Free cash flow | −47 | −33 | −61 | −73 | −70 |
Recent filings
- 4Insider transaction report
Oct 5, 2026 - 4Insider transaction report
Sep 21, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KEntry into a material agreement
Jun 12, 2026 - 8-KRegulation FD disclosure
Jun 11, 2026 - 8-KAmendment to articles or bylaws
Jun 10, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026